To receive your instant certificate, you must "Sign In" or "Sign Up" in the top right corner.
EXPIRATION: October 31, 2020
MAXIMUM CREDITS: 1.5 AMA PRA Category 1 Credits™ and 1.5 contact hours
CLICK HERE TO PROCEED TO POST TEST, EVALUATION, AND CERTIFICATE
Psychotic symptoms occur during the course of Parkinson disease in up to 60% of patients. These progressive symptoms range in severity from mild hallucinations to disruptive delusions that might drastically affect the quality of life of patients and their caregivers alike and increase the likelihood of patient institutionalization. Patients with severe symptoms are often prescribed antipsychotics that lack evidence of efficacy for Parkinson disease psychosis and might have adverse effects that jeopardize patient safety. The efficacy and adverse effects associated with many commonly used antipsychotics, such as quetiapine, clozapine, and risperidone, can be explained by examining their broad receptor-binding profile. Pimavanserin, a newer agent used to treat Parkinson disease psychosis, binds specifically to the 5-hydroxytryptamine 2A and 2C receptors, minimizing the risk of adverse effects. The desired outcome of this activity is for psychiatrists, neurologists, physician assistants, nurses, social workers, and psychologists to recognize psychosis in Parkinson disease as part of the progressive disease process and treat symptoms effectively while maintaining safety and quality of life of patients who might be residing in long-term care.
To view/print the CME/CE monograph, click below.